SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more
SillaJen Inc (215600) - Total Liabilities
Latest total liabilities as of September 2025: ₩6.58 Billion KRW
Based on the latest financial reports, SillaJen Inc (215600) has total liabilities worth ₩6.58 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SillaJen Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how SillaJen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SillaJen Inc Competitors by Total Liabilities
The table below lists competitors of SillaJen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥373.70 Million |
|
Beijing ConST Instruments Technology Inc
SHE:300445
|
China | CN¥118.87 Million |
|
Scimee Sci &Tech Co Ltd
SHE:300425
|
China | CN¥1.97 Billion |
|
M. Dias Branco S.A. Indústria e Comércio de Alimentos
SA:MDIA3
|
Brazil | R$4.77 Billion |
|
Anhui Gourgen Traffic Construction Co Ltd
SHG:603815
|
China | CN¥7.49 Billion |
|
Fujian SuperTech Advanced Material Co Ltd
SHG:688398
|
China | CN¥944.51 Million |
|
Eventbrite Inc Class A
NYSE:EB
|
USA | $555.47 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down SillaJen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SillaJen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SillaJen Inc (2015–2024)
The table below shows the annual total liabilities of SillaJen Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.20 Billion | -11.35% |
| 2023-12-31 | ₩19.40 Billion | -20.83% |
| 2022-12-31 | ₩24.51 Billion | -8.49% |
| 2021-12-31 | ₩26.78 Billion | +9.11% |
| 2020-12-31 | ₩24.54 Billion | -12.67% |
| 2018-12-31 | ₩28.11 Billion | -14.85% |
| 2017-12-31 | ₩33.01 Billion | -56.66% |
| 2016-12-31 | ₩76.16 Billion | +15.23% |
| 2015-12-31 | ₩66.09 Billion | -- |